Insights

Public Benefit Position NOVOS operates as a Public Benefit Corporation and donates profits and equity to longevity-focused nonprofits. This can be leveraged in outreach to impact-driven partners, grantmakers, and corporate sustainability teams seeking purpose-aligned collaborations and co-branded initiatives.

Longevity Market Fit Strong emphasis on science-backed nutraceuticals targeting aging mechanisms suggests opportunities for partnerships with health tech platforms, aging-focused clinics, wellness retailers, and direct-to-consumer channels that cater to longevity and preventive health.

Expert Network A roster of high-profile scientific advisors from top institutions enhances credibility. Sales outreach can highlight access to expert-led content, co-creation opportunities, and potential white-label or collaboration products appealing to premium customers and institutions.

Education & Content Free educational resources on healthy longevity are available. This content can be repurposed for lead generation, community building, and partner education programs to drive awareness, trial, and affiliate opportunities without direct product pressure.

Financial Outlook Current revenue is modest with recent funding and visible growth potential. Target partnerships with distributors or co-marketing with lifestyle brands and biotech-focused funds to accelerate market reach and validate value in broader consumer and institutional channels.

Similar companies to NOVOS

NOVOS Tech Stack

NOVOS uses 8 technology products and services including Criteo, html5media, oEmbed, and more. Explore NOVOS's tech stack below.

  • Criteo
    Advertising
  • html5media
    Audio, Video, Graphics
  • oEmbed
    Dev Tools
  • Choices
    Javascript Libraries
  • Lodash
    Javascript Libraries
  • SweetAlert2
    Javascript Libraries
  • Convertcart
    Marketing Automation
  • Tailwind CSS
    UI Frameworks

NOVOS's Email Address Formats

NOVOS uses at least 1 format(s):
NOVOS Email FormatsExamplePercentage
First@novoslabs.comJohn@novoslabs.com
96%
FirstL@novoslabs.comJohnD@novoslabs.com
4%

Frequently Asked Questions

What is NOVOS's stock symbol?

Minus sign iconPlus sign icon
NOVOS is a publicly traded company; the company's stock symbol is 688052.SS.

What is NOVOS's official website and social media links?

Minus sign iconPlus sign icon
NOVOS's official website is novoslabs.com and has social profiles on LinkedInCrunchbase.

How much revenue does NOVOS generate?

Minus sign iconPlus sign icon
As of July 2026, NOVOS's annual revenue is estimated to be $10M - $25M.

What is NOVOS's SIC code NAICS code?

Minus sign iconPlus sign icon
NOVOS's SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does NOVOS have currently?

Minus sign iconPlus sign icon
As of July 2026, NOVOS has approximately 33 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Principal Software Engineer: A. H.. Explore NOVOS's employee directory with LeadIQ.

What industry does NOVOS belong to?

Minus sign iconPlus sign icon
NOVOS operates in the Biotechnology Research industry.

What technology does NOVOS use?

Minus sign iconPlus sign icon
NOVOS's tech stack includes Criteohtml5mediaoEmbedChoicesLodashSweetAlert2ConvertcartTailwind CSS.

What is NOVOS's email format?

Minus sign iconPlus sign icon
NOVOS's email format typically follows the pattern of First@novoslabs.com. Find more NOVOS email formats with LeadIQ.

How much funding has NOVOS raised to date?

Minus sign iconPlus sign icon
As of July 2026, NOVOS has raised $7.2M in funding. The last funding round occurred on Jan 01, 2022 for $3.1M.

When was NOVOS founded?

Minus sign iconPlus sign icon
NOVOS was founded in 2018.
NOVOS logo

NOVOS

Biotechnology ResearchNew York, United States11-50 Employees

NOVOS is a biotechnology company based in New York City that develops nutraceuticals aimed at slowing aging and extending human lifespan. Its products are grounded in current scientific research and are developed with input from aging researchers, using ingredients with evidence of lifespan effects in various organisms and in humans to target the 12 mechanisms of aging for potential synergistic benefits. The company maintains a scientific advisory group comprising biochemists, geneticists, and professors from institutions including Harvard, MIT, the University of Liverpool, the University of Washington, and the Salk Institute. NOVOS operates as a Public Benefit Corporation and donates a portion of profits and equity to longevity-focused nonprofits such as the Life Extension Advocacy Foundation (LEAF). It also publishes free educational content on its blog to inform the public about living longer and healthier lives, regardless of product use.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
688052.SS
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
11-50

Section iconFunding & Financials

  • $7.2M

    NOVOS has raised a total of $7.2M of funding over 3 rounds. Their latest funding round was raised on Jan 01, 2022 in the amount of $3.1Mas a angel.

  • $10M - $25M

    NOVOS's revenue is estimated to be in the range of $10M - $25M

Section iconFunding & Financials

  • $7.2M

    NOVOS has raised a total of $7.2M of funding over 3 rounds. Their latest funding round was raised on Jan 01, 2022 in the amount of $3.1Mas a angel.

  • $10M - $25M

    NOVOS's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.